Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEPEN vs CUVRIOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
Wilson's disease,Cystinuria,Rheumatoid arthritis,Heavy metal poisoning (e.g., lead, mercury)
Treatment of Wilson disease in patients intolerant to penicillamine,Off-label: treatment of copper overload in other conditions
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
300 mg subcutaneously once daily.
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours.
Penicillamine is metabolized via oxidation to disulfides. It is primarily excreted in urine as unchanged drug and metabolites.
Metabolized mainly by conjugation and oxidation; minor involvement of CYP450 enzymes.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose.
80%; primarily to albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
0.1-0.4 L/kg; indicates limited extravascular distribution, mainly confined to plasma and interstitial fluid.
Vd is approximately 0.2–0.3 L/kg, indicating distribution largely confined to plasma and extracellular fluid.
Oral: 40-70% (variable due to food and formulation).
Not administered orally due to poor absorption; bioavailability by oral route is negligible.
GFR 30-59 m L/min: 250 mg every 8-12 hours; GFR 15-29 m L/min: 250 mg every 12-24 hours; GFR <15 m L/min: 250 mg every 24 hours or avoid use.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No adjustment recommended for mild to moderate impairment (Child-Pugh A or B); avoid use in severe impairment (Child-Pugh C) due to increased risk of hepatotoxicity.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C).
Children >1 year: 10-15 mg/kg/day divided every 6-8 hours, maximum 500 mg/day.
Safety and efficacy not established in pediatric patients.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal function decline; monitor renal function and adjust based on creatinine clearance.
No specific dose adjustment recommended; clinical studies included a limited number of patients aged ≥65 years, with no overall differences in safety or efficacy observed.
None.
None
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia),Proteinuria and nephrotic syndrome,Autoimmune reactions (lupus-like syndrome, myasthenia gravis),Hepatotoxicity,Severe skin reactions (e.g., pemphigus, Stevens-Johnson syndrome),Monitor renal function, blood counts, and urinalysis regularly
Monitor for iron deficiency due to copper chelation,May cause lupus-like syndrome,Monitor liver function tests,Use with caution in patients with renal impairment
History of penicillamine-induced aplastic anemia or agranulocytosis,Pregnancy (relative contraindication due to teratogenicity),Renal insufficiency (avoid in severe impairment),Hypersensitivity to penicillamine
Hypersensitivity to trientine or any component,Rheumatoid arthritis (due to potential exacerbation of symptoms),Use in pregnancy only if clearly needed
Avoid foods high in copper (e.g., liver, shellfish, nuts, chocolate, mushrooms) during treatment for Wilson disease. For cystinuria, maintain high fluid intake (at least 3-4 liters/day) and reduce sodium and animal protein to decrease cystine excretion. Vitamin B6 supplementation may be needed as DEPEN can increase pyridoxine requirements.
Take CUVRIOR on an empty stomach: at least 1 hour before meals or 2 hours after meals. Avoid high-copper foods such as chocolate, nuts, shellfish, liver, mushrooms, and whole grains. Avoid dairy products and milk within 1 hour of dosing as calcium may reduce absorption. Iron supplements and zinc supplements should be taken at least 2 hours apart from CUVRIOR.
Penicillamine (Depen) is associated with severe fetal malformations including cutis laxa and skeletal abnormalities when used during pregnancy. First trimester exposure carries highest risk; use is contraindicated unless necessary for maternal conditions like Wilson's disease or cystinuria. Second and third trimester use may cause fetal connective tissue disorders.
CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Copper deficiency from aggressive chelation may increase teratogenic risk; therefore, maintaining copper levels within the therapeutic range is critical. First trimester: highest risk for malformations; second and third trimesters: risk of fetal copper deficiency and impaired development if maternal copper is overchelated.
Penicillamine is excreted into breast milk in low amounts; M/P ratio not well defined. Potential for infant toxicity (e.g., rash, bone marrow suppression). Caution advised; monitor infant for adverse effects. Alternative therapies preferred.
It is unknown whether trientine is excreted in human milk. Caution should be exercised when administered to a nursing woman. The M/P ratio is not established. Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No standard dose adjustment defined; use lowest effective dose. Pharmacokinetics not well studied; increased clearance may require dose titration. Monitor clinical response and copper levels in Wilson's disease.
Physiologic changes in pregnancy (increased plasma volume, enhanced renal clearance) may reduce trientine concentrations, potentially requiring dose adjustments. However, specific pharmacokinetic data in pregnancy are lacking. The goal is to maintain copper levels within the therapeutic range; doses may need to be increased to prevent under-chelation, but careful monitoring is essential to avoid over-chelation and copper deficiency. Dose adjustments should be individualized based on serum copper levels and clinical response.
DEPEN (penicillamine) is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for proteinuria and hematuria due to immune complex nephropathy. Cross-sensitivity with penicillin possible. Administer on empty stomach for Wilson disease; with meals for cystinuria to reduce GI upset. Avoid concomitant use with other nephrotoxic drugs.
CUVRIOR (trientine hydrochloride) is a copper-chelating agent used for Wilson disease. Monitor urinary copper excretion and serum free copper (non-ceruloplasmin bound) to guide dosing. Avoid concurrent use with zinc supplements or other chelators due to antagonism. Administer on an empty stomach (1 hour before or 2 hours after meals) and separate from other medications by at least 1 hour. Iron deficiency anemia can occur due to copper depletion; check iron studies periodically. Neurological worsening may occur early in therapy; use lower starting doses in patients with neurological symptoms.
Take DEPEN on an empty stomach at least 1 hour before or 2 hours after meals, unless otherwise directed for cystinuria.,Do not skip doses; consistent intake is critical for Wilson disease to prevent copper accumulation.,Report any signs of infection, unusual bleeding, skin rash, or changes in urine color or output immediately.,Avoid alcohol completely as it may increase risk of liver toxicity.,Use effective contraception during therapy as DEPEN can cause fetal harm.,Have regular blood and urine tests as ordered to monitor for side effects.
Take CUVRIOR on an empty stomach, at least 1 hour before or 2 hours after meals.,Separate CUVRIOR from other medications, supplements, or antacids by at least 1 hour.,Do not take CUVRIOR with milk, dairy products, or iron supplements.,Report any new or worsening neurological symptoms, such as tremors, difficulty speaking, or trouble walking, to your doctor immediately.,Regular blood tests are required to monitor copper levels and liver function.,Do not stop taking CUVRIOR abruptly; consult your doctor before making any changes.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEPEN vs CUVRIOR, answered by our medical review team.
DEPEN is a Chelating Agent that works by Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.. CUVRIOR is a Chelating Agent that works by CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEPEN and CUVRIOR depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEPEN is: 250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.. The standard adult dose of CUVRIOR is: 300 mg subcutaneously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEPEN and CUVRIOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEPEN is classified as Category C. Penicillamine (Depen) is associated with severe fetal malformations including cutis laxa and skeletal abnormalities when used during pregnancy. First trimester exposure carries hig. CUVRIOR is classified as Category C. CUVRIOR (trientine) is classified as Pregnancy Category C. In animal studies, trientine has been shown to be embryocidal and teratogenic at doses similar to the human dose. There a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.